Cardlytics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the period ending September 30, 2024, for Cardlytics, Inc. (CDLX), a Delaware corporation headquartered in Atlanta, Georgia. The filing reports a material definitive agreement entered into on the reporting date.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, or liquidity. The report focuses exclusively on the restructuring of the company's debt facility.
Material Changes
- Debt Restructuring: On September 30, 2024, the Company entered into an amended and restated loan and security agreement with Banc of California, N.A. (formerly Pacific Western Bank).
- Consolidation: The new agreement consolidates the original 2018 Loan and Security Agreement and all subsequent amendments into a single document.
- Terms: Except for immaterial changes, the terms of the new agreement are consistent with the existing agreement previously disclosed in the Company's 2023 Form 10-K and Q2 2024 Form 10-Q.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, management outlook, or discussion of risks beyond the standard disclosure that the agreement description is qualified by reference to the full text of the agreement. The full agreement is intended to be filed as an exhibit to the Quarterly Report on Form 10-Q for the quarter ended September 30, 2024.
Investor Verification Checklist
- Verify the specific interest rates, covenants, and maturity dates in the full text of the amended agreement (to be filed as an exhibit to the Q3 2024 10-Q).
- Confirm the total outstanding principal balance under the consolidated facility.
- Review the Q3 2024 10-Q for any impact of this agreement on liquidity or working capital.